- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00165828
Efficacy and Safety of an add-on Treatment With Zonisamide in Adults With Focal Epileptic Seizures With or Without Secondary Generalization
June 26, 2014 updated by: Eisai GmbH
Randomized Trial to Assess Efficacy and Safety of an add-on Treatment With Zonisamide in Adults With Focal Epileptic Seizures With or Without Secondary Generalization
Patients with focal epileptic seizures with or without generalization who are at present treated with one or two antiepileptic drugs are eligible for this study, provided that they fulfill all inclusion criteria and none of the exclusion criteria.
Following a baseline phase of 8 weeks duration, the patients are randomised and they receive an initial daily dose of 50 mg zonisamide during the first week.
The daily dose is then increased to 200 mg zonisamide in group A or 400 mg zonisamide in group B, respectively.
After eight weeks of treatment, the daily dose in group A can be increased to 300 mg in case of insufficient efficacy.
Control assessments are performed at the beginning of the study and at the end of the prospective baseline phase, if applicable and after 4, 8, 12, and 16 weeks.
At the end of the first, second, and third treatment week, and at the end of week six, the patient is additionally contacted by telephone.
Efficacy and safety parameters are assessed at baseline, during all control visits, and at the end of the study.
Study Overview
Study Type
Interventional
Enrollment (Actual)
157
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Beilefeld, Germany, 33617
- Epilepsiezentrum Bethel/KSE
-
Berlin, Germany, 10362
- Institut fur Diagnostik der Epilepsien Gmbh
-
Berlin, Germany, 13353
- Charite Campus Virchow-Klinikum, Neurologische Klinik und Poliklinik
-
Bochum, Germany, 44791
- St. Josephs Hospital, Neurologische Klinik
-
Bochum, Germany, 44805
- Dr. Gunther Schumann
-
Bochum, Germany, 44892
- Knappschaftskrankenhaus Bochum-Langendreer, Neurologische Klinik
-
Bonn, Germany, 53127
- Dr. Hans Martin Kolbinger
-
Dusseldorf, Germany, 40212
- Neuro-Consil Gmbh
-
Erlangen, Germany, 91054
- Neurologische Klinik der Universitat Erlangen
-
Essen, Germany, 45147
- Universitatsklinik Essen, Klinik und Poliklinik fur Neurologie
-
Freiburg, Germany, 79106
- Universitatsklinikum Freiburg, Neurozentrum
-
Gottingen, Germany, 37075
- Universitatsklinikum Gottingen, Abt. fur klinische Neurophysiologie
-
Hamburg, Germany, 22083
- Gemeinschaftpraxis fur Neurologie und Psychiatrie
-
Hamburg, Germany, 22299
- Dr. Heinrich C. Braeuer
-
Hamburg, Germany, 22337
- Ev. Krankenhaus Alsterdorf, Epilepsiezentrum Alsterdorf
-
Kehl, Germany, 77694
- Epilepsiezentrum Kork
-
Liegau-Augustusbad, Germany, 01465
- Epilepsiezentrum Kleinwachau, Epilepsieambulanz
-
Mannheim, Germany, 68167
- Universitatsklinikum Mannheim, Neurologische Klinik, Ambulanz fur Anfallserkrankte
-
Marburg, Germany, 35043
- Universitatsklinikum, Interdisziplinares Epilepsiezentrum
-
Munchen, Germany, 81377
- Klinikum Grosshadern, Neurologische Klinik und Poliklinik, Epilepsie-Ambulanz
-
Offenbach, Germany, 63069
- Klinikum Offenbach, Neurologie
-
Potsdam, Germany, 14467
- Klinik Ernst von Bergmann
-
Regensburg, Germany, 93053
- Universitat Regensburg, Klinik un Poliklinik fur Neurologie
-
Revensburg, Germany, 88214
- Klinik "Die Weissenau", Anfallsambulanz
-
Rostock, Germany, 18147
- Universitat Rostock, Klinik fur Neurologie und Poliklinik
-
Ulm, Germany, 89075
- Universitatsklinik Ulm Poliklinik fur Neurologie, Epilepsieambulanz
-
Wiesbaden, Germany, 65199
- Dr. Horst-Schmidt Klinik, Neurologie
-
-
Brandenburg
-
Bernau, Brandenburg, Germany, 16321
- Epilepsieklinik Tabor
-
-
Nordrhein-Westphalen
-
Bonn, Nordrhein-Westphalen, Germany, 53105
- Universtitatsklinikum Bonn
-
Munster, Nordrhein-Westphalen, Germany, 48129
- Universtitatsklinikum Munster, Klinik und Poliklinik fur Neurologie
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 74 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion criteria at screening:
- Adult aged between 18 years and 74 years
- Focal epileptic seizures with or without secondary generalization
- Present treatment with one or two antiepileptic drugs (constant dosage during 8 weeks baseline phase prior to initiation of treatment with zonisamide). Stimulation of the vagus nerve is permitted and will not be counted as antiepileptic drug.
- For women of childbearing potential (postmenopausal for more than 1 year): possible pregnancy during the study can be excluded (by hysterectomy, sterilization or simultaneous application of two recognized methods of contraception (no oral contraceptives only)
- For male patients with partners of childbearing potential: a safe method of contraception is practiced during their study participation
- Written consent to participate in the study
Inclusion criteria for randomisation:
- At least 6 focal or clonicotonic seizures documented completely in a seizure diary or the patient chart during the 8 prospective or retrospective weeks baseline phase.
Exclusion criteria at screening:
- Epileptic state during the past year
- Non-epileptic fits
- Generalized epilepsy
- More than 4 weeks of seizure freedom during baseline phase
- Concomitant progressive CNS disease including progressive myoclonus epilepsy
- Concomitant treatment with vigabatrine and / or topiramate
- Hepatic and/or renal insufficiency (creatine > 2mg% or GPT > 2 times ULN)
- Body weight ≤ 40 kg
- (History of) kidney stones; erythrocyturia, family history (in parents, children, brothers and sisters or grandparents) of kidney stones
- (History of) drug and/or alcohol dependence
- Active psychosis
- Suicide attempt during the past 3 years
- Pre-treatment with zonisamide
- Known hypersensitivity to sulfonamides
- concomitant treatment with neuroleptic drugs
- pregnant or breast feeding woman
- participation in another therapy study within 3 months prior to or during this study
- blood donation planned during or within 4 weeks after the participation in this study
- elective surgery planned during the participation in this study
- patient is not willing or not capable to meet the study demands
- patient does not agree to the forwarding of his/her pseudonymous data
- patient without legal competence
Exclusion criteria for randomisation:
- More than 4 consecutive weeks of freedom from seizure during baseline phase
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
|
Intravenous injection; initial daily dose of 50 mg zonisamide (2x25 mg) in both treatment groups; following a prospective or retrospective baseline phase of 8 weeks the study drug will be administered twice daily during 16 consecutive weeks.
|
Experimental: 2
|
Intravenous injection; initial daily dose of 50 mg zonisamide (2x25 mg) in both treatment groups; following a prospective or retrospective baseline phase of 8 weeks the study drug will be administered twice daily during 16 consecutive weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in number of epileptic seizures between week 13 and 16 after start of treatment compared to the correspondently normalized base-line phase.
Time Frame: 28 days
|
28 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Christian Elger, Universitatsklinikum Bonn, Klinik fur Epileptologie
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2005
Primary Completion (Actual)
February 1, 2008
Study Completion (Actual)
February 1, 2008
Study Registration Dates
First Submitted
September 13, 2005
First Submitted That Met QC Criteria
September 13, 2005
First Posted (Estimate)
September 14, 2005
Study Record Updates
Last Update Posted (Estimate)
June 27, 2014
Last Update Submitted That Met QC Criteria
June 26, 2014
Last Verified
November 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Epilepsy
- Seizures
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Membrane Transport Modulators
- Anticonvulsants
- Calcium-Regulating Hormones and Agents
- Calcium Channel Blockers
- Zonisamide
Other Study ID Numbers
- ZNS-D-04-001
- 2005-000260-57 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Epilepsy
-
NaviFUS CorporationTaipei Veterans General Hospital, TaiwanCompletedDrug Resistant Epilepsy | Epilepsy, Drug Resistant | Intractable Epilepsy | Refractory Epilepsy | Drug Refractory Epilepsy | Epilepsy, Drug Refractory | Epilepsy, Intractable | Medication Resistant EpilepsyTaiwan
-
Great Ormond Street Hospital for Children NHS Foundation...Active, not recruitingEpilepsies, Partial | Intractable Epilepsy | Focal Epilepsy | Refractory Epilepsy | Epilepsy Intractable | Epilepsy in Children | Epilepsy, FocalUnited Kingdom
-
University of British ColumbiaTerminatedJuvenile Myoclonic Epilepsy | Childhood Absence Epilepsy | Juvenile Absence EpilepsyCanada
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruiting
-
Neuroelectrics CorporationRecruitingEpilepsy | Seizures | Refractory Epilepsy | Epilepsy, Tonic-Clonic | Epilepsy in Children | Seizures, Focal | Focal SeizureSpain, United States, France, Belgium
-
Oslo University HospitalCompletedEpilepsy | Generalized Epilepsy | Focal EpilepsyNorway
-
UCB Pharma SACompletedEpilepsy, Tonic-clonicPoland, Sweden, Hungary, Czechia
-
UCB PharmaCompletedEpilepsy, Tonic-clonic
-
University Hospital, LilleUnknownFocal Epilepsy | Epilepsy IntractableFrance
-
Xuanwu Hospital, BeijingPeking University; Beijing Tiantan Hospital; Qilu Hospital of Shandong University and other collaboratorsNot yet recruitingEpilepsy, Drug ResistantChina
Clinical Trials on Zonegran
-
Dr. Reddy's Laboratories LimitedCompleted
-
Dr. Reddy's Laboratories LimitedCompleted
-
Mutual Pharmaceutical Company, Inc.Completed
-
Mutual Pharmaceutical Company, Inc.Completed
-
Eisai Inc.Eisai Farmacêutica S.A.Completed
-
Eisai LimitedTerminatedEpilepsyAustralia, Serbia, Germany, Czech Republic, Romania, Estonia, Lithuania, Croatia, Finland, Hungary, Poland, Russian Federation, Ukraine
-
The Cooper Health SystemSuspendedParkinson Disease | Dyskinesias | ParkinsonismUnited States
-
Eisai LimitedCompleted
-
Eisai LimitedCompletedEpilepsyUnited Kingdom, France, Germany, Italy, Austria, Denmark, Norway